'Faster together': AstraZeneca breaks into clinical services business with new company launch, lining up two CRO partners to start
LONDON — AstraZeneca has launched a new global health tech business, Evinova, after seeing a gap in the market to reduce the time and cost of clinical trials while making the process easier for patients.
Financially backed by AstraZeneca but operating as a separate business, Evinova will provide global services to CROs and pharma companies to design, run and monitor clinical trials. Evinova will charge customers for access to its tech, operating on a revenue-based model.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.